News and Comments

Knowing Better About Gilead and Amgen. The Mess and Miss Following the Storm

  Friday, February 05, 2016

Gilead Sciences More...

AMGN: Rapatha Approved In Europe

  Tuesday, July 21, 2015

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol More...

CYTOKINETICS: THE MOMENT OF HALF THE TRUTH

  Friday, April 25, 2014

Bad news has come from Cytokinetics' (CYTK) top-line results of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Bottom line, BENEFIT-ALS trial did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group, p = 0.11). Another ambitious attempt to decrease some of ALS burden on the sufferers has disappointed.  
 More...

AMGEN INVESTIGATIONAL DRUG ROMOSOZUMAB IS PROMISING FOR POSTMENOPAUSAL OSTEOPOROSIS

  Thursday, January 02, 2014

Osteoporosis is caused by a progressive decrease in bone mass and density which increases the risk of fracture. The reduced, bone mineral density (BMD) impacts the bone architecture and alters the amount and variety of proteins in the bones.  More...

YES AMGEN IS THE KING

  Wednesday, December 18, 2013

When Amgen (AMGN) develops a drug, the wise King does whatever it takes to squeeze every drop of its therapeutic capability before submitting the new drug application (NDA) to the FDA for approval. The firm is rich in its science, scientists, pipeline of investigational products and its approved products. All the problems the firm encountered that analysts believed would erode its fortune, such as limiting the use of its growth factors did not impact the firm’s growth, but unveiled the character and culture that made the king deserve its throne.   More...

BIOTECHNOLOGY: ON THE WAY TO MEETING HIGHLY AMBITIOUS EXPECTATIONS

  Wednesday, September 05, 2012

 More...

Regeneron & Amgen: More Breakthrough Drugs In The Horizon

  Wednesday, November 16, 2011

In controlling high cholesterol levels statins have reigned for a very long time, generating over $30 billion/year with products like Lipitor and crestor generating almost ten million/year each. Statins act by blocking HMG-CoA reductase, an enzyme required for the production of LDL, (the bad cholesterol) in the liver. Statins side effects could be severe. They can cause muscle damage. Some physicians believe they are overprescribed, as 30 million Americans currently take the cholesterol pills. More...

Monster Blockbuster Anti-Cholesterol Drugs In Biotechs’ Pipelines

  Wednesday, August 31, 2011

The new biological science is evolving at the speed of light. As a matter of fact, the bright penetrating light of the genomic revolution is effectively reaching the dark corners where the utmost reality remained hidden since millions of years. The new light enabled the insight to match the sight in divulging the buried secrets of body at the molecular level. With the most advanced tools ever created by human minds, scientists have reached a stage where they can spend much less effort in solving much more puzzles on the road towards solving the problems of diseases at their root-origin. The successful are those researchers who keep their eyes open and their minds prepared. More...

CYTOKINETICS’ NEW PLAN WITH AMGEN INCREASES THE DOSE OF OPTIMISM TOWARDS THE H.F. DRUG.

  Sunday, February 06, 2011

In the news, Cytokinetics (CYTK) announced that, in the first half of 2011, the company and Amgen (AMGN) have agreed to initiate a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil for patients with left ventricular systolic dysfunction hospitalized for acute heart failure. Amgen will conduct the trial in collaboration with Cytokinetics.  More...

XOMA (XOMA): What would erase investors’ reservations?

  Thursday, November 11, 2010

According to data from its IL-1 beta inhibitor drug Xoma 052 in patients with uveitis, all seven patients with Behcet's uveitis enrolled in the XOMA 052 trial experienced rapid reduction of intraocular inflammation and improvement in visual acuity following a single treatment with the drug. A recent data presented at the 2010 American College of Rheumatology Scientific meeting demonstrate that all the five patients re-treated with XOMA 052 due to a recurring uveitis exacerbation have responded all over again to XOMA 052 and maintained their response for several months. Cytokine data showed reduced levels of IL-1 beta, IL-1 alpha and IL-6, as compared to baseline, with an increase in the levels of interferon gamma, which protects against infection.  More...


Recent Postings


Archive


Tags

Jazz Pharmaceuticals (JAZZ) TOKAI (TKAOI) Anadys (ANDS) Prolor Biotech (PBTH) OSI (OSIP) Sanofi (SNY) Multiple Myeloma Illumina (ILMN) Array Pharmaceuticals (ARRY) Theravance Bio Pharma (TBPH) NEKTAR (NKTR)) Intermune (ITMN) Merck (MRK) Incyte (INCY) Valeant Pharmaceuticals International (VRX) Genentech Human Longevity (HLI) JUNO (JUNO) Trastuzumab-DM1 ABBVIE (ABBV) KERYX (KERX) AERIE PHARMACEUTICALS ImmunoGen (IMGN) SUNESIS PHARMACEUTICALS (SNSS) Sangamo (SGMO) Aimmune Therapeutics (AIMT) Auspex (ASPX) Sanofi-Aventis (SAN) Inovio (INO) ARCA (ABIO) Galena (GALE) Abbott Laboratories (ABT) ADVENTRIX (ANX) SYNTA (SNTA) C4 Therapeutics Human Genome Sciences (HGSI) Sequenom (SQNM) Sanofi (SNA) ZALTRAP™ ISIS (ISIS) Tysabri Mirati Therapeutics (MRTX) VANDA (VNDA) Roche (ROCHE) Regeneron (REGN) REGULUS (RGLS) Exelixis (EXEL) Amgen (AMGN) Theravance (THRX) Telaprevir Biocryst (BCRX) Alder Biopharmaceuticals (ALDR) Seattle Genetics (SGEN) Biogen Idec (BIIB) Dendreon (DNDN) Sarepta (SRPT) Ridaforolimus Roche (RHHBY) Zerenex Ziofpharm (ZIOP) ACADIA (ACAD) Onyx (ONXX) galapagos (GLPG) Pluristem (PSTI) Ariad (ARIA) Herceptin Cytokinetics (CYTK) Micromet (MITI) Agenus (AGEN) NANTKWEST (NK) Dynavax (DVAX) Alnylam (ALNY) Benlysta (belimumab) Intrexon (XON) Gilead (GILD) Prosensa (RNA) GlaxoSmithKline (GSK) Ionis (IONS) KITE (KITE) Xoma (XOMA) Bristol-Myers Squibb (BMY) CompuGen (CGEN) HALOZYME (HALO) GUARDIAN HEALTH Idenix (IDIX) Vertex (VRTX) BIOMARIN (BMRN) Intercept (ICPT) IDERA (IDRA) Elan (ELN) Anacor (ANAC) Velcade (bortezomib) Agenus (AGEN Endometrial Cancer Rapamune Vitae Pharmaceuticals (VTAE) SERES THERAPEUTICS (MCRB) Revlimid (lenolidamide)